βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2235-2249

  McCarroll, Joshua A ^a,b   Sharbeen, George ^a   Liu, Jie ^a   Youkhana, Janet ^a   Goldstein, David ^a,c   McCarthy, Nigel ^b   Limbri, Lydia F ^a   Dischl, Dominic ^d   Ceyhan, Güralp O ^d   Erkan, Mert ^e   Johns, Amber L ^f   Biankin, Andrew V ^f,g   Kavallaris, Maria ^a,b   Phillips, Phoebe A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e KOÇ UNIVERSITY   (Turkey)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Chemoresistance; Metastases; Pancreatic cancer; Tumor growth; III tubulin

Indexed keywords

BETA TUBULIN; BETA3 TUBULIN; GEMCITABINE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; TUBB3 PROTEIN, HUMAN; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CLONOGENESIS; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANOIKIS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNAI THERAPEUTICS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923052438     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2946     Document Type: Article

References (47)

1. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010; 362(17):1605-1617.
2. Klein AP. Genetic susceptibility to pancreatic cancer. Molecular carcinogenesis. 2012; 51(1):14-24.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014; 74(11):2913-2921.
4. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63(1):11-30.
5. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M. Pancreatic cancer. Lancet. 2011; 378(9791):607-620.
6. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(33):5660-5669.
7. Raimondi S, Maisonneuve P and Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nature reviews Gastroenterology & hepatology. 2009; 6(12):699-708.
8. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D and Sarkar FH. Pancreatic cancer: understanding and overcoming chemoresistance. Nature reviews Gastroenterology & hepatology. 2011; 8(1):27-33.
9. Zalatnai A and Molnar J. Review. Molecular background of chemoresistance in pancreatic cancer. In vivo. 2007; 21(2):339-347.
10. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH. Recent progress in pancreatic cancer. CA: a cancer journal for clinicians. 2013; 63(5):318-348.
11. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nature reviews Cancer. 2010; 10(3):194-204.
12. Jordan MA and Kamath K. How do microtubule-targeted drugs work? An overview. Current cancer drug targets. 2007; 7(8):730-742.
13. Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ and Di Leo A. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical breast cancer. 2002; 3(5):341-345.
14. Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina E, Togo AV, Kornilov AV, Ivantsov AO and Imyanitov EN. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Medical oncology. 2013; 30(2):545.
15. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G and Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(1):298-305.
16. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. British journal of cancer. 1998; 77(4):562-566.
17. Seve P and Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? The lancet oncology. 2008; 9(2):168-175.
18. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL and Dumontet C. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(15):5481-5486.
19. Guo J, Qiang M and Luduena RF. The distribution of beta-tubulin isotypes in cultured neurons from embryonic, newborn, and adult mouse brains. Brain research. 2011; 1420:8-18.
20. Verdier-Pinard P, Pasquier E, Xiao H, Burd B, Villard C, Lafitte D, Miller LM, Angeletti RH, Horwitz SB and Braguer D. Tubulin proteomics: towards breaking the code. Analytical biochemistry. 2009; 384(2):197-206.
21. Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S and Ferlini C. betaIII-Tubulin: biomarker of taxane resistance or drug target? Expert opinion on therapeutic targets. 2013; 17(4):461-472.
22. Gan PP, Pasquier E and Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer research. 2007; 67(19):9356-9363.
23. Kavallaris M, Burkhart CA and Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. British journal of cancer. 1999; 80(7):1020-1025.
24. McCarroll JA, Gan PP, Liu M and Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer research. 2010; 70(12):4995-5003.
25. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F and de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer research. 2010; 70(22):9253-9264.
26. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A and Ouellette MM. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology. 2007; 51(4):539-546.
27. Dozier JH, Hiser L, Davis JA, Thomas NS, Tucci MA, Benghuzzi HA, Frankfurter A, Correia JJ and Lobert S. Beta class II tubulin predominates in normal and tumor breast tissues. Breast cancer research: BCR. 2003; 5(5):R157-169.
28. Gan PP and Kavallaris M. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer research. 2008; 68(23):9817-9824.
29. Hiser L, Aggarwal A, Young R, Frankfurter A, Spano A, Correia JJ and Lobert S. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell motility and the cytoskeleton. 2006; 63(1):41-52.
30. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G and Ferlini C. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(9):2774-2779.
31. Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S and Quaas A. betaIII-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. The American journal of pathology. 2013.
32. Vilmar AC, Santoni-Rugiu E and Sorensen JB. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(15):5205-5214.
33. Yang YL, Luo XP and Xian L. The Prognostic Role of the Class III beta-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis. PloS one. 2014; 9(4):e93997.
34. Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S, Scambia G and Ferlini C. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer research. 2010; 70(14):5891-5900.
35. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G and Ferlini C. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene. 2008; 409(1-2):100-108.
36. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G and Ferlini C. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. Journal of cellular physiology. 2012; 227(3):1034-1041.
37. Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H and Kleeff J. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer biology & therapy. 2008; 7(9):1352-1359.
38. Xu D, Allsop SA, Witherspoon SM, Snider JL, Yeh JJ, Fiordalisi JJ, White CD, Williams D, Cox AD and Baines AT. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis. 2011; 32(4):488-495.
39. Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, Scambia G and Ferlini C. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Molecular cancer therapeutics. 2008; 7(7):2070-2079.
40. Taddei ML, Giannoni E, Fiaschi T and Chiarugi P. Anoikis: an emerging hallmark in health and diseases. The Journal of pathology. 2012; 226(2):380-393.
41. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, Vickers SM and Saluja AK. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer research. 2007; 67(19):9407-9416.
42. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J and Tsao MS. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. The American journal of pathology. 2000; 157(5):1623-1631.
43. Byrne FL, Yang L, Phillips PA, Hansford LM, Fletcher JI, Ormandy CJ, McCarroll JA and Kavallaris M. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene. 2014; 33(7):882-890.
44. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA and Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Molecular cancer therapeutics. 2010; 9(5):1339-1348.
45. Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, Dawra R, Lerch MM and Saluja A. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer research. 2007; 67(2):616-625.
46. Phillips PA, Sangwan V, Borja-Cacho D, Dudeja V, Vickers SM and Saluja AK. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer letters. 2011; 308(2):181-188.
47. McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang ZQ, Grizzle WE, Stockard CR, Nash KT and Buchsbaum DJ. KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clinical & experimental metastasis. 2010; 27(8):591-600.